DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Phase 3

Conditions: Irritable Bowel Syndrome

Interventions: Drug: 25mg Eluxadoline
Drug: 100mg Eluxadoline

First Posted Date: 2021-05-11

Last Posted Date: 2024-06-18

Lead Sponsor: AbbVie

Target Recruit Count: 124

Registration Number: NCT04880876

Locations: 🇺🇸
Florida Research Center, Inc. /ID# 227597, Miami, Florida, United States
🇺🇸
Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 227600, Stockbridge, Georgia, United States
🇺🇸
Preferred Primary Care Physicians, Inc. /ID# 227596, Pittsburgh, Pennsylvania, United States

and more 1 locations

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977

Phase 3

Conditions: Psoriasis

Interventions: Drug: Risankizumab

First Posted Date: 2021-04-27

Last Posted Date: 2024-06-17

Lead Sponsor: AbbVie

Target Recruit Count: 132

Registration Number: NCT04862286

Locations: 🇩🇪
Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 243883, Kiel, Schleswig-Holstein, Germany
🇺🇸
First OC Dermatology /ID# 226942, Fountain Valley, California, United States
🇺🇸
Solutions Through Adv Rch /ID# 226104, Jacksonville, Florida, United States

and more 36 locations

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis

Phase 2

Terminated

Conditions: Cystic Fibrosis (CF)

Interventions: Drug: Placebo
Drug: ABBV-576
Drug: Navocaftor
Drug: Galicaftor
Drug: ABBV-119

First Posted Date: 2021-04-21

Last Posted Date: 2024-07-16

Lead Sponsor: AbbVie

Target Recruit Count: 48

Registration Number: NCT04853368

Locations: 🇺🇸
University of Southern California /ID# 249147, Los Angeles, California, United States
🇺🇸
UH Cleveland Medical Center /ID# 245433, Cleveland, Ohio, United States
🇺🇸
Boston Children's Hospital /ID# 248646, Boston, Massachusetts, United States

and more 38 locations

A Study of the Change in Early and Sustained Pain Control in Axial Spondylarthritis in Adult Participants Receiving Upadacitinib

Completed

Conditions: Axial Spondylarthritis (axSpA)

First Posted Date: 2021-04-15

Last Posted Date: 2025-04-03

Lead Sponsor: AbbVie

Target Recruit Count: 708

Registration Number: NCT04846244

Locations: 🇬🇷
University General Hospital of Patras /ID# 243795, RION Patras Achaia, Greece
🇧🇪
ReumaClinic /ID# 231438, Genk, Belgium
🇦🇷
Hospital Italiano La Plata /ID# 230779, La Plata, Buenos Aires, Argentina

and more 157 locations

Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications

Recruiting

Conditions: Other Conditions for Which Risankizumab is an FDA-approved Treatment
Plaque Psoriasis
Crohn Disease
Psoriatic Arthritis

Interventions: Drug: Risankizumab
Drug: Comparator

First Posted Date: 2021-04-15

Last Posted Date: 2024-03-06

Lead Sponsor: AbbVie

Target Recruit Count: 818

Registration Number: NCT04846959

Locations: 🇺🇸
Evidera, a PPD Business Unit /ID# 238688, Morrisville, North Carolina, United States
🇺🇸
PPD Development, LP /ID# 232134, Wilmington, North Carolina, United States

A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of Age

Phase 3

Completed

Conditions: Presbyopia

Interventions: Drug: AGN-190584
Drug: Vehicle

First Posted Date: 2021-04-08

Last Posted Date: 2024-10-10

Lead Sponsor: AbbVie

Target Recruit Count: 43

Registration Number: NCT04837482

Locations: 🇦🇺
School of Optometry and Vision Science, Queensland University of Technology /ID# 226378, Brisbane, Queensland, Australia

RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)

Phase 2

Completed

Conditions: Wet Macular Degeneration
Wet Age-related Macular Degeneration
Neovascular Age-related Macular Degeneration

Interventions: Genetic: RGX-314

First Posted Date: 2021-04-06

Last Posted Date: 2024-04-12

Lead Sponsor: AbbVie

Target Recruit Count: 60

Registration Number: NCT04832724

Locations: 🇺🇸
Wilmer Eye Institute, Baltimore, Maryland, United States
🇺🇸
Retina Consultants of Texas, The Woodlands, Texas, United States
🇺🇸
California Retina Consultants, Santa Barbara, California, United States

and more 10 locations

Expanded Access to Telisotuzumab Vedotin

Conditions: Non-Small Cell Lung Cancer (NSCLC)

First Posted Date: 2021-04-05

Last Posted Date: 2025-04-04

Lead Sponsor: AbbVie

Registration Number: NCT04830202

Locations: 🇺🇸
Oncology & Hematology Specialist /ID# 248083, Mountain Lakes, New Jersey, United States
🇺🇸
Sutter Medical Group /ID# 254816, Sacramento, California, United States
🇦🇺
Western Heamatology and Oncology Clinics /ID# 243364, West Perth, Western Australia, Australia

and more 6 locations

Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants Above 19 Years of Age With Acute Myeloid Leukemia (AML)

Recruiting

Conditions: Acute Myeloid Leukemia (AML)

First Posted Date: 2021-04-01

Last Posted Date: 2024-06-20

Lead Sponsor: AbbVie

Target Recruit Count: 600

Registration Number: NCT04826523

Locations: 🇰🇷
Kosin University Gospel Hospital /ID# 257399, Busan, Busan Gwang Yeogsi, Korea, Republic of
🇰🇷
Gachon University Gil Medical Center /ID# 239008, Incheon, Gyeonggido, Korea, Republic of
🇰🇷
Kyungpook National University Hospital /ID# 257398, 중구, Daegu Gwang Yeogsi, Korea, Republic of

and more 7 locations

Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine

Phase 1

Completed

Conditions: Migraine

Interventions: Drug: Atogepant
Drug: Ubrogepant

First Posted Date: 2021-03-26

Last Posted Date: 2022-06-16

Lead Sponsor: AbbVie

Target Recruit Count: 26

Registration Number: NCT04818515

Locations: 🇺🇸
PPD Clinical Research Unit /ID# 227676, Orlando, Florida, United States
🇺🇸
Bio-Kinetic Clinical Applications, LLC /ID# 227675, Springfield, Missouri, United States
🇺🇸
Spaulding Clinical Research LLC /ID# 229505, West Bend, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy